FDA issues Complete Response Letter for Galderma’s Relfydess BLA, citing manufacturing inspection observations and analytical method optimization; no clinical safety or efficacy concerns identified. Global approvals and launches continue across 33 markets as Galderma works toward rapid U.S. resubmission.
Written By: Umesh Hanumante,
M.Pharm (Reg. Affairs)
Reviewed By: Pharmacally Editorial Team
Galderma has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) of Relfydess (relabotulinumtoxinA), delaying the product’s entry into the U.S. aesthetic market. The agency’s comments were limited to observations made during a Pre-License Inspection (PLI) of the company’s manufacturing facility and the need for analytical method optimization.
the FDA did not identify deficiencies related to the product’s clinical safety, efficacy, or other components of the BLA. The company stated it is implementing corrective and preventive actions to address the inspection findings and will continue working closely with the FDA before submitting its response to the CRL. Advancing Relfydess in the United States remains a strategic priority.
Clinical and Technology Background
Relfydess is Galderma’s ready-to-use liquid formulation of relabotulinumtoxinA, developed for aesthetic indications. Unlike conventional botulinum toxin products that require reconstitution before administration, Relfydess is supplied as a liquid formulation manufactured using the company’s proprietary PEARL Technology, which preserves the integrity of the active neurotoxin molecule.
According to Galderma, clinical studies showed that up to 39% of patients experienced visible treatment effects on the first day, while up to 75% maintained aesthetic improvements for six months. The ready-to-use formulation also provides standardized volumetric dosing, eliminating reconstitution variability during administration.
Manufacturing Findings Do Not Affect Global Commercialization
The FDA’s observations are specific to the U.S. regulatory review and do not affect approvals or commercialization outside the United States.
Relfydess has now received regulatory approval in 33 markets and has been commercially launched in more than 20 countries, including across Europe, the United Kingdom, the Middle East, Asia, and Australia. Galderma reported encouraging early commercial uptake supported by positive feedback from healthcare professionals.
The company also noted that the same manufacturing facility has successfully completed 10 inspections by major international regulatory authorities since 2022, supporting approvals in multiple global markets. Regulatory submissions in additional countries continue as planned.
Company Focuses on Rapid FDA Response
Galderma said it is actively implementing corrective measures to address the FDA’s manufacturing observations while maintaining ongoing dialogue with the agency to facilitate resolution. The company intends to submit its response to the CRL as quickly as possible.
Beyond Relfydess, Galderma continues expanding its injectable aesthetics pipeline through internally integrated research, development, manufacturing, and commercialization capabilities. The company expects ongoing international regulatory reviews and commercial launches for Relfydess to proceed without disruption while it works toward securing U.S. approval.
Reference
About the Writer
Umesh Hanumante (M.Pharm) (LinkedIn) is a pharmacy professional and healthcare writer with a background in Regulatory Affairs, pharmaceutical innovation, and clinical research. He has around two years of industry experience as an Executive PMT at Troikaa Pharmaceuticals Ltd and qualified GPAT 2024. His areas of interest include regulatory compliance, dossier preparation, clinical trials, emerging therapies, and advancements in the global pharmaceutical and healthcare sector.